Evidence map›Paper›PMID 28621528›Full record

ArticleAnalytical chemistry2017

Unsupervised Discovery and Comparison of Structural Families Across Multiple Samples in Untargeted Metabolomics.

Justin J J van der Hooft, Joe Wandy, Francesca Young, Sandosh Padmanabhan, Konstantinos Gerasimidis, Karl E V Burgess, Michael P Barrett, Simon Rogers

Open access · hybridAbstract readComparative Study
In one paragraph

Article in Analytical chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 71 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. A Relook into the Flavonoid Chemical Space ofJournal of analytical methods in chemistry · 2023
    Article
  11. Identifying xenobiotic metabolites withFrontiers in toxicology · 2023
    Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Justin J J van der HooftGlasgow Polyomics, University of Glasgow , Glasgow G61 1HQ, United Kingdom.
Joe WandyGlasgow Polyomics, University of Glasgow , Glasgow G61 1HQ, United Kingdom.
Francesca YoungGlasgow Polyomics, University of Glasgow , Glasgow G61 1HQ, United Kingdom.
Sandosh PadmanabhanInstitute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow , Glasgow G12 8QQ, United Kingdom.
Konstantinos GerasimidisHuman Nutrition, School of Medicine, College of Medical, Veterinary and Life Sciences, University of Glasgow , New Lister Building, Glasgow Royal Infirmary, Glasgow G31 2ER, United Kingdom.
Karl E V BurgessGlasgow Polyomics, University of Glasgow , Glasgow G61 1HQ, United Kingdom.
Michael P BarrettGlasgow Polyomics, University of Glasgow , Glasgow G61 1HQ, United Kingdom.
Simon RogersGlasgow Polyomics, University of Glasgow , Glasgow G61 1HQ, United Kingdom.
University of Glasgow · GBGlasgow Royal Infirmary · GB

Funding

Biotechnology and Biological Sciences Research Council BB/L018616/1Medical Research Council MR/N005813/1Wellcome Trust
6 · The paper itself

Abstract

In untargeted metabolomics approaches, the inability to structurally annotate relevant features and map them to biochemical pathways is hampering the full exploitation of many metabolomics experiments. Furthermore, variable metabolic content across samples result in sparse feature matrices that are statistically hard to handle. Here, we introduce MS2LDA+ that tackles both above-mentioned problems. Previously, we presented MS2LDA, which extracts biochemically relevant molecular substructures ("Mass2Motifs") from a collection of fragmentation spectra as sets of co-occurring molecular fragments and neutral losses, thereby recognizing building blocks of metabolomics. Here, we extend MS2LDA to handle multiple metabolomics experiments in one analysis, resulting in MS2LDA+. By linking Mass2Motifs across samples, we expose the variability in prevalence of structurally related metabolite families. We validate the differential prevalence of substructures between two distinct samples groups and apply it to fecal samples. Subsequently, within one sample group of urines, we rank the Mass2Motifs based on their variance to assess whether xenobiotic-derived substructures are among the most-variant Mass2Motifs. Indeed, we could ascribe 22 out of the 30 most-variant Mass2Motifs to xenobiotic-derived substructures including paracetamol/acetaminophen mercapturate and dimethylpyrogallol. In total, we structurally characterized 101 Mass2Motifs with biochemically or chemically relevant substructures. Finally, we combined the discovered metabolite families with full scan feature intensity information to obtain insight into core metabolites present in most samples and rare metabolites present in small subsets now linked through their common substructures. We conclude that by biochemical grouping of metabolites across samples MS2LDA+ aids in structural annotation of metabolites and guides prioritization of analysis by using Mass2Motif prevalence.

Indexed as

Drug DiscoveryMetabolomicsModels, StatisticalAdolescentAgedAged, 80 and overAntihypertensive AgentsBeerChildChromatography, LiquidFecesFemaleHumansMaleMass SpectrometryMiddle AgedAntihypertensive Agents

Identifiers

PMID28621528
PMCPMC5524435
OpenAlexW2626886916

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.